From GlobeNewswire:

CVRx, Inc. plans to release fourth quarter 2023 financial and operating results after market close on Thursday, January 25th, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area.

Investor Contact for CVRx, Inc.is Mark Klausner or Mike Vallie at ICR Westwicke. Contact at 443-213-0501 or email [email protected]. Media contact is Laura O’Neill at Finn Partners, contact her at 212-867-1762 or email [email protected].



Read more: CVRx to Report Fourth Quarter 2023 Financial and Operating